Imbruvica – Display Banners Conference – 55240
ASH 2022: Leukemia eBook
Focus on ASH Leukemia 2023.indd
Factors Associated With Improved COVID-19 Outcomes for CLL
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
MRD by qPCR Prognostic of Outcomes in Venetoclax-Treated, NPM1-Mutated AML
Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...
Excellent Results for Triplet Regimen in FLT3-Mutated AML
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Ibrutinib Delays Need for Next Treatment in Real-World First-Line CLL
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Blinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
